NCT06565273View on ClinicalTrials.gov

Study to Investigate the Efficacy, Safety, and Tolerability of FBL-MTX in Patients With Rheumatoid Arthritis

PHASE2RecruitingINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

July 24, 2024

Primary Completion Date

July 31, 2025

Study Completion Date

July 31, 2025

Conditions
Rheumatoid Arthritis
Interventions
DRUG

FBL-MTX

Patients will be administered an initial dose of FBL-MTX by subcutaneous route. Subsequent doses will be titrated according to clinical response. Maximum dosage will be 2.5 mg, every 2 weeks.

Trial Locations (8)

3814-501

RECRUITING

Unidade Local de Saúde da Região de Aveiro, EPE, Aveiro

4710-243

RECRUITING

Unidade Local de Saúde de Braga, EPE, Centro Clínico Académico de Braga (2CA-Braga), Braga

6300-858

RECRUITING

Unidade Local de Saúde da Guarda, EPE, Guarda

4835-044

RECRUITING

Unidade Local de Saúde do Alto Ave, EPE, Guimarães

2410-197

RECRUITING

Unidade Local de Saúde da Região de Leiria, EPE, Leiria

4990-041

RECRUITING

Unidade Local de Saúde do Alto Minho, EPE, Ponte de Lima

4200-319

RECRUITING

Unidade Local de Saúde de São João, EPE, Porto

4434-502

RECRUITING

Unidade Local de Saúde de Gaia e Espinho, EPE, Vila Nova de Gaia

All Listed Sponsors
lead

SOLFARCOS - Pharmaceutical and Cosmetic Solutions Ltd

OTHER